EMA Offers Simultaneous Review Of Products For EU And Non-EU Markets
Move Will Reduce Time For Article 58 Opinion On Medicines To Be Also Used In EU
Companies can have their EU centralized marketing authorization application and submission for an Article 58 opinion (on medicines for use in non-EU countries) reviewed in parallel by the European Medicines Agency. The simultaneous assessment can be helpful when drugs and vaccines are needed for both EU and non-EU populations.
